Teva Pharmaceutical (NYSE:TEVA) is shipping out a new product. The company announced it has launched the authorized generic form of Pfizer's Detrol LA on the U.S. market. The drug will be sold in both two milligram and four milligram capsules.
Detrol LA is used to treat overactive bladder symptoms such as leaks and excessive urination frequency.
The drug is the latest addition to Teva's broad portfolio of generic products. The company is coming off a challenging 2013, in which it saw its CEO depart, and the patent protection expiration date of its top-branded product, multiple sclerosis treatment Copaxone, brought forward in a legal dispute.
Teva is scheduled to report its Q4 2013 results on February 6. On average, analysts are expecting EPS of $1.40 on revenue of $5.2 billion. In Q4 2012, the firm posted a per-share loss of $1.32 and top line of $5.2 billion.
Fool contributor Eric Volkman has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.